K. Andersen

发表

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

Time since childbirth and prognosis in primary breast cancer: population based study

H. Mouridsen, M. Melbye, K. Andersen, 1997, BMJ.

Parity, age at first childbirth and the prognosis of primary breast cancer.

H. Mouridsen, M. Melbye, K. Andersen, 1998, British Journal of Cancer.

Steroid hormone receptors as prognostic indicators in primary breast cancer.

B. Rasmussen, H. Mouridsen, C. Rose, 1986, Breast cancer research and treatment.

Regional trends in breast cancer incidence and mortality in Denmark prior to mammographic screening.

H. Mouridsen, K. Andersen, E. Lynge, 1994, British Journal of Cancer.

Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen

H. Mouridsen, K. Andersen, B. Ejlertsen, 2005, Breast Cancer Research and Treatment.

Bone metastases in primary operable breast cancer. The role of serial scintigraphy.

H. Thomsen, K. Andersen, O. Munck, 1984, European journal of cancer & clinical oncology.

Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer

H. Mouridsen, K. Andersen, H. Brincker, 2005, Breast Cancer Research and Treatment.

Variations in prognostic factors in primary breast cancer throughout the menstrual cycle.

H. Mouridsen, K. Andersen, N. Kroman, 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.

L. Bastholt, H. Mouridsen, P. Dombernowsky, 1986, Breast cancer research and treatment.

Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: present status of Danish Breast Cancer Cooperative Group trials.

H. Mouridsen, P. Dombernowsky, C. Rose, 1986, NCI monographs : a publication of the National Cancer Institute.

Prognostic significance of residual cancer tissue after diagnostic biopsy in breast carcinoma. Three-year short-term results.

H. Mouridsen, J. Kjaergaard, K. Andersen, 1984, European journal of cancer & clinical oncology.

Organisation of the Danish adjuvant trials in breast cancer.

M. Ro̸rth, H. Mouridsen, H. Johansen, 1981, Danish medical bulletin.

Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.

H. Mouridsen, C. Rose, K. Andersen, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Quality control of end results in a Danish adjuvant breast cancer multi-center study.

H. Mouridsen, K. Andersen, P. S. Hansen, 1997, Acta oncologica.

18. Risk factors and survival of local recurrence (LR) as first site local relapse after treatment of invasive breast cancer (IBC)

K. Andersen, M. Nielsen, J. Andersen, 1995 .

Bone metastases in primary operable breast cancer. The role of a yearly scintigraphy.

P. Dombernowsky, H. Thomsen, K. Andersen, 1987, European journal of cancer & clinical oncology.

Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer.

B. Rasmussen, C. Rose, K. Andersen, 1986, Cancer research.

What do early bone scans tell about breast cancer patients?

O Munck, N Rossing, K. Andersen, 1982, European journal of cancer & clinical oncology.

Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections.

C. Rose, K. Andersen, P. Pfeiffer, 1996, British Journal of Cancer.

Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials.

J. Peterse, H. Bartelink, R. Sylvester, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

Jack Cuzick, R. Collins, J. Crowley, 1988 .

Re: Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer

D. Machin, K. Andersen, 1997 .

Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group.

H. Mouridsen, C. Rose, K. Andersen, 1992, Journal of the National Cancer Institute. Monographs.

Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group.

J. Peterse, H. Bartelink, I. Fentiman, 1999, European journal of cancer.

BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES

B. Rasmussen, H. Mouridsen, C. Rose, 1985, The Lancet.

Anti-estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: 72 months of life-table analysis and steroid hormone receptor status

H. Mouridsen, C. Rose, K. Andersen, 1985, World Journal of Surgery.

Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C.

B. Rasmussen, H. Mouridsen, P. Dombernowsky, 1988, Acta oncologica.

Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer.

H. Mouridsen, K. Andersen, H. Mouridsen, 1988, Acta oncologica.

Argyrophilic cells in 202 human mucinous breast carcinomas. Relation to histopathologic and clinical factors.

B. Rasmussen, C. Rose, K. Hou‐Jensen, 1985, American journal of clinical pathology.

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer.

D. Machin, K. Andersen, 1997, Journal of the National Cancer Institute.

Selection of High Risk Groups Among Prognostically Favorable Patients with Breast Cancer: An Analysis of the Value of Prospective Grading of Tumor Anaplasia in 1,048 Patients

H. Johansen, E. Henriksen, K. Hou‐Jensen, 1981, Annals of surgery.

Adjuvant systemic treatment and the pattern of recurrences in patients with breast cancer.

K. Zedeler, C. Rose, K. Andersen, 1988, European journal of cancer & clinical oncology.

Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B.

H. Mouridsen, P. Dombernowsky, C. Rose, 1988, Acta oncologica.

Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.

H. Mouridsen, P. Dombernowsky, C. Rose, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Danish randomized trial comparing breast-preserving therapy with mastectomy in mammary carcinoma. Preliminary results.

G. Knudsen, H. Mouridsen, P. Dombernowsky, 1988, Acta oncologica.

Stage and pattern of metastases in patients with breast cancer.

C Kamby, K. Zedeler, C. Rose, 1987, European journal of cancer & clinical oncology.

Prognostic Usefulness of Estrogen Receptor Iimminocvtocheniical Assays for Human Breast Cancer 1

B. Rasmussen, C. Rose, K. Andersen, 2006 .

Antiestrogen treatment of postmenopausal women with primary high risk breast cancer

H. Mouridsen, C. Rose, K. Andersen, 1983, Breast Cancer Research and Treatment.

Pattern of metastases in human breast carcinoma in relation to estrogen receptor status.

C. Rose, K. Andersen, N. Holm, 1986, Anticancer research.

Strategy in the management of in situ carcinomas of the breast: clinical, diagnostic, and surgical aspects.

K. Andersen, J. Andersen, U. Dyreborg, 1990, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis.

C. Rose, S. Bentzen, K. Andersen, 1998, British Journal of Cancer.

Timing of surgery in relation to menstrual cycle does not predict the prognosis in primary breast cancer. Danish Breast Cancer Cooperative Group.

H. Mouridsen, K. Andersen, N. Kroman, 1994, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[Adjuvant endocrine treatment of postmenopausal patients with breast cancer with high risk of recurrence. 5. Results from the DBCG (Danish Breast Cancer Cooperative Group) 77C randomized trial].

H. Mouridsen, P. Dombernowsky, C. Rose, 1991, Ugeskrift for læger.

[Adjuvant chemotherapy in premenopausal and menopausal high-risk patients with breast cancer. 4. Results of the DBCG (Danish Breast Cancer Cooperative Group) 77B study].

B. Rasmussen, H. Mouridsen, P. Dombernowsky, 1991, Ugeskrift for laeger.

Classical prognostic factors in node-negative breast cancer: the DBCG experience.

B. Rasmussen, H. Mouridsen, P. Dombernowsky, 1992, Journal of the National Cancer Institute. Monographs.

[The pattern of metastases in breast cancer and the relation to estrogen receptor status].

C. Rose, K. Andersen, N. Holm, 1986, Ugeskrift for læger.